71,316 Shares in Bausch Health Companies Inc. (NYSE:BHC) Bought by Prescott Group Capital Management L.L.C.

Prescott Group Capital Management L.L.C. acquired a new stake in Bausch Health Companies Inc. (NYSE:BHC) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 71,316 shares of the company’s stock, valued at approximately $571,000.

Several other large investors have also recently made changes to their positions in the business. Public Sector Pension Investment Board increased its holdings in Bausch Health Companies by 7.3% during the first quarter. Public Sector Pension Investment Board now owns 602,663 shares of the company’s stock worth $4,876,000 after buying an additional 41,211 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Bausch Health Companies by 4.2% in the 2nd quarter. Mackenzie Financial Corp now owns 1,138,717 shares of the company’s stock worth $9,110,000 after purchasing an additional 45,768 shares during the period. BNP Paribas Arbitrage SNC lifted its stake in Bausch Health Companies by 17,200.6% in the first quarter. BNP Paribas Arbitrage SNC now owns 3,016,183 shares of the company’s stock valued at $24,431,000 after purchasing an additional 2,998,749 shares during the last quarter. Barclays PLC grew its holdings in Bausch Health Companies by 198.5% during the second quarter. Barclays PLC now owns 954,226 shares of the company’s stock valued at $7,633,000 after purchasing an additional 634,551 shares during the period. Finally, Mach 1 Financial Group LLC purchased a new stake in Bausch Health Companies in the first quarter worth $15,148,000. 74.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 6,685 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $8.28, for a total value of $55,351.80. Following the transaction, the executive vice president now directly owns 385,213 shares in the company, valued at approximately $3,189,563.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.75% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BHC has been the subject of several recent research reports. Royal Bank of Canada lifted their price objective on Bausch Health Companies from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Monday, July 24th. StockNews.com lowered shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, Jefferies Financial Group raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and raised their price objective for the stock from $9.00 to $16.00 in a report on Wednesday, September 20th.

Bausch Health Companies Price Performance

NYSE:BHC traded up $0.08 during mid-day trading on Monday, hitting $6.98. 551,924 shares of the stock traded hands, compared to its average volume of 3,638,228. The business’s 50-day moving average price is $7.60 and its 200 day moving average price is $7.90. The company has a quick ratio of 0.89, a current ratio of 1.20 and a debt-to-equity ratio of 74.20. The company has a market cap of $2.52 billion, a PE ratio of -2.61 and a beta of 0.98. Bausch Health Companies Inc. has a 12-month low of $5.57 and a 12-month high of $10.23.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.